Connecticut startup momentum tops last year’s pace

In filings to the U.S. Securities & Exchange Commission between January and March of this year, Connecticut companies reported raising $109 million in the aggregate, more than five times what they secured in the first quarter of 2018

Investors have lined up to back life sciences spinouts in New Haven such as Arvinas and Biohaven Pharmaceuticals.

New Haven-based Kleo Pharmaceuticals led all Connecticut companies in funding. Kleo is developing synthetic compounds that “recruit” the immune system into destroying cancer cells.